What have we learnt from Vioxx?

British Medical Journal

Volumn 334, Issue 7585, 2007, Pages 120-123

  Krumholz, Harlan ^a   Ross, Joseph S ^b   Presler, Amos H ^c   Egilman, David S ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Never Again Consulting   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; NAPROXEN; PROSTACYCLIN; ROFECOXIB;

CLINICAL FEATURE; CLINICAL TRIAL; COMPENSATION; DRUG EFFICACY; DRUG INDICATION; DRUG INHIBITION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HEALTH CARE POLICY; HEART INFARCTION; HUMAN; INCIDENCE; LEARNING; LEGAL ASPECT; LONG TERM CARE; MEDICAL LITERATURE; MEDICAL RECORD; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; THROMBOGENESIS; UNITED STATES;

EID: 33846642973     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39024.487720.68     Document Type: Review

References (22)

1. United States Securities and Exchange Commission. Form 10-Q: quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 (Note 7 to consolidated financial statements). Merck, 2006; http://phx.corporate-ir.net/phoenix.zhtml?c=73184& p=irolSECText&TEXT= aHROcDovL2NjYm4uMTBrd2l6YXJ kLmNvbS94bWwvZmlsaW5nLnht bD9yZXBvPXRIbmsmaXBhZ2U9NDMxNDgxMiZkb2 M9MSZudW09MTI=.
2. Merck. Vioxx (rofecoxib): frequently asked questions. www.vioxx.com/rofecoxib/vioxx/consumer/faq.jsp.
3. Morrison BW. Memo to Alan Nies, Barry Gertz, Beth Seidenberg. Letter to Ken Lasseter; manuscript draft for protocol 023. 18 Feb, 1998. Merck. Bates Nos MRK-NJ0017794 to MRK-NJ0017822. www.vioxxdocuments.com/Documents/ Krumholz_Vioxx/Morrison1998.pdf
4. Food and Drug Administration, Division of Anti-Inflammatory, Analgesic, and Ophthalmic Drug Products. HFD-550, medical officer review. Vioxx (rofecoxib), NDA 21-042/052. Washington, DC: FDA, 1999.
5. Food and Drug Administration. FDA advisory committee briefing document NDA 21-042, s007: VIOXX gastrointestinal safety. Washington, DC: 2001.
6. Merck. Vioxx. In response to your questions: cardiovascular system, clinical profile in osteoarthritis studies. Whitehouse Station NJ: Merck, 2000. www.vioxxdocuments.com/Documents/Krumholz_Vioxx/Merck2000CVcard.pdf.
7. Waxman HA. Merck documents show aggressive marketing of Vioxx after studies indicated risk. US House of Representatives Committee on Government Reform, 2005. www.democrats.reform.house.gov/story.asp?ID =848&Issue= Prescription+Drugs.
8. Waxman HA. Memo re: the marketing of Vioxx to physicians. Washington, DC: US House of Representatives, 2005.
9. Weinblatt M. Memo to Drs. Bjorkman, Neaton, Shapiro, Silman, and Sturrock re: Interim non-endpoint safety analysis of VIGOR-unblinded minutes. November 18,1999. Found in sNDAS-007: P088C: Appendix 3.9.2 at p.2939-2946 (Bates No. MRK-00420015464-MRK-00420015471. www.vioxxdocuments.com/ Documents/Krumholz_Vioxx/VigorDSMB.pdf.
10. Merck. Medical affairs procedures and policies. Procedure 23: collaborative research efforts and megatrials. Appendix 2: Merck guidelines for data and safety monitoring boards. 29 Feb, 1999. Bates Nos MRK-AFK0047772 to AFK0047791. www.vioxxdocuments.com/Documents/Krumholz_Vioxx/ Merck1999guidelines.pdf.
11. Reicin AS. Letter re: financial disclosure for Merck and Co, Inc sponsored protocol entitled: "A double-blind, randomized, stratified, parallel-group study to assess the incidence of PUBs during chronic treatment with MK-0966 ornaproxen in patients with rheumatoid arthritis (VIGOR)." 4 Feb, 2000. Merck. Bates Nos MRK-MEW00012 to MRK-MEW00014. www.vioxxdocuments.com/Documents/Krumholz_Vioxx/ReicinWeinblatt2000.pdf.
12. Merckand Co. Multidisciplinary strategic advisory board for cox-2 inhibitors, consulting agreement. February 29, 2000. Bates Nos MRK-STI0037747 to STI0037751. www.vioxxdocuments.com/Documents/Krumholz_Vioxx/ WeinblattContract.pdf.
13. Scolnick EM. Email communication to Deborah Shapiro, Alise Reicin, and Alan Nies re: Vigor. 9 Mar, 2000. Bates No MRK-ABH0016219. www.vioxxdocuments.com/Documents/Krumholz_Vioxx/Scolnick2000.pdf.
14. Drazen JM. Hidden data counfounds medical journal editors. Wall Street Journal 2006 May 19:A11.
15. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese J, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-81.
16. Fries JF. Letter to Raymond Gilmartin re: physician intimidation. 9 Jan, 2001. Merck. Bates No MRK-ABH0002204 to MRK-ABH0002207. www.vioxxdocuments.com/Documents/Krumholz_Vioxx/Fries2001.pdf.
17. Morrison BW. Email communication to Rhonda Sperling, Alise Reicin, Deborah Shapiro, et al. re: fw: for review [peer]: 2001-ms-2470 (full paper) - due date Monday, 27 August 2001. 17 Aug, 2001. Bates Nos MRK-ACF0005697 to MRK-ACF0005699. www.vioxxdocuments.com/Documents/Krumholz_Vioxx/Morrison2001. pdf.
18. Meier B, Kolata G, Pollack A. Medicine fueled by marketing intensified trouble for pain pills. New York Times 2004 Dec 19:A1.
19. Meier B, Saul S. Marketing of Vioxx: how Merck played game of catch-up. New York Times 2005 Feb 11:A1.
20. Berenson A, Harris G, Meier B, Pollack A. Dangerous data-retracing a medical trail. New York Times 2004 Nov 14:A1.
21. IMS Health. National prescription audit plus time period 1999 to September 2004, extracted 2004. Plymouth Meeting, PA: IMS Health, 2004.
22. Targum SL. Review of cardiovascular safety database, rofecoxib. NDA 21-042, S-007. Washington, DC: FDA, 2001. www.fda.gov/ohrms/dockets/ac/01/ briefing/3677b2_06_cardio.pdf. References w1-w37 are on bmj.com